Genalyte, a US-based diagnostics technology developer that counts biotech real estate firm BioMed Realty as an investor, closed $36m in funding co-led by Khosla Ventures and Redmile Group on Monday.
Genalyte has created a microchip-equipped diagnostics platform called the Maverick Detection System which can give laboratory test results to patients in a doctor’s office in under 15 minutes from a single drop of blood.
Cary Gunn, founder and chief executive of Genalyte, said: “Genalyte will be using these funds to fully develop our platform, and to prove performance through additional clinical studies.”
The funding will be added to the $44m in series C capital Genalyte raised from BioMed Realty’s corporate venturing unit, BioMed Realty Ventures, as well as Khosla, Redmile and Claremont Creek Ventures in August 2015.
BioMed participated in the 2015 round as an existing investor, according to Genalyte. The company had previously received $11.8m in a 2012 series B round featuring Redmile Group and Claremont Creek Ventures.